Document is current
Any future updates will be listed below
-
Authors
Naghavian, Reza https://orcid.org/0000-0002-1328-4095
Faigle, Wolfgang
Oldrati, Pietro https://orcid.org/0000-0001-5551-4306
Wang, Jian
Toussaint, Nora C. https://orcid.org/0000-0001-7911-7647
Qiu, Yuhan https://orcid.org/0000-0002-5774-7661
Medici, Gioele https://orcid.org/0000-0003-2279-6014
Wacker, Marcel https://orcid.org/0000-0002-8185-140X
Freudenmann, Lena K.
Bonté, Pierre-Emmanuel https://orcid.org/0000-0002-9732-5826
Weller, Michael https://orcid.org/0000-0002-1748-174X
Regli, Luca https://orcid.org/0000-0003-4639-4474
Amigorena, Sebastian https://orcid.org/0000-0001-8583-8416
Rammensee, Hans-Georg
Walz, Juliane S. https://orcid.org/0000-0001-6404-7391
Brugger, Silvio D. https://orcid.org/0000-0001-9492-9088
Mohme, Malte https://orcid.org/0000-0003-0627-9092
Zhao, Yingdong
Sospedra, Mireia
Neidert, Marian C.
Martin, Roland https://orcid.org/0000-0002-0982-1329
- License Information
-
More Information
Article History
Received: 7 June 2022
Accepted: 13 April 2023
First Online: 17 May 2023
Competing interests
: R.N., W.F. and M.S. are currently employees of Cellerys AG. R.M. received unrestricted grants from Biogen, Novartis, Roche, Third Rock; has advisory roles and lectures for Roche, Novartis, Biogen, Merck, Genzyme, Neuway, CellProtect, Third Rock and Teva; is listed as an inventor on a NIH-held patent of daclizumab in MS and University of Zurich-held patents on JCV VP1 for vaccination against PML, JCV-specific neutralizing antibodies to treat PML, antigen-specific tolerization with peptide-coupled cells and novel autoantigens in MS, the use of designer neoantigens for glioblastoma (inventor R.M.), and of peptides and TCRs shown in this study for the personalized treatment of glioblastoma (inventors R.N., J.W. & R.M.); and is a co-founder of Abata, and a co-founder and employee of Cellerys AG. L.K.F. is an employee of Immatics Biotechnologies. M.C.N. has received a research grant from Novocure, and honoraria for consulting or lectures from WISE, MSD and Novocure. M.Weller has received research grants from Quercis and Versameb, and honoraria for lectures or advisory board participation or consulting from Bayer, Curevac, Medac, Merck (EMD), Novartis, Novocure, Orbus, Philogen, Roche and Sandoz.
